SPTX
HEALTHCARESeaport Therapeutics, Inc. Common Stock
What's Moving SPTX Today?
No stock-specific AI insight has been generated for SPTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$20.51
Fundamentals
Trading
SPTX News
5 articles- PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy VolunteersYahoo Finance·Jun 9, 2026
- Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical ProgressYahoo Finance·Jun 8, 2026
- Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy VolunteersYahoo Finance·Jun 8, 2026
- Seaport Therapeutics to Participate in Two Upcoming Investor ConferencesYahoo Finance·Jun 1, 2026
- Assessing Seaport Therapeutics (SPTX) Valuation After Its Recent 10.2% One Day Share Price MoveYahoo Finance·May 4, 2026
All 5 articles loaded
Price Data
52-Week Range
$20.51
Fundamentals
Trading
About Seaport Therapeutics, Inc. Common Stock
Seaport Therapeutics, Inc. (SPTX) is a pioneering biopharmaceutical firm dedicated to addressing significant unmet medical needs through the development of innovative immune-oncology therapies. Utilizing advanced technologies and a comprehensive research pipeline, the company focuses on creating targeted treatment options for complex diseases, especially cancer. Seaport's strategic collaborations and partnerships enhance its capabilities within the dynamic therapeutics sector, while its experienced management team drives its mission to improve patient outcomes and transform the landscape of cancer treatment. With a clear commitment to scientific advancement, Seaport Therapeutics is poised to play a vital role in the future of immunotherapy.